Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Hmm,

<< Previous

Bullboard Posts

Next >>

Comment by Red~Oneon Oct 19, 2021 1:01pm

124 Views

Post# 34023187

RE:Hmm,

If that was Shorts covering they would be buying at the ASK not selling into the Bid as far as I know if Shorts are in this stock they would already have sold and be waiting for a drop to BUY those shares. Isn't that the way it would work?

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs